🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  2. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  3. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  4. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  5. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  6. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  7. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  8. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  9. SPD503 (Guanfacine hydrochloride)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  10. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  11. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  12. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  13. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  14. STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend).

    The George Institute

    Yellow fever

    phase 3 small molecule active

    1 trial

  15. SUBLOCADE

    Indivior Pty Ltd

    Opioid Use Disorder

    phase 3 small molecule terminated

    2 trials

  16. SUBOXONE

    Indivior Pty Ltd

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  17. SUBOXONE sublingual film

    Indivior Pty Ltd

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  18. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  19. Sabin Strain Inactivated Poliovirus Vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  20. Sacubitril-Valsartan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    STEMI

    phase 3 small molecule active

    1 trial

  21. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  22. Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, Inhalation powder with lactose monohydrate and magnesium stearate, BREO ELLIPTA, Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg

    Sandoz Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  23. Saline (0.9%, sterile, for infusion)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumocystis Jiroveci Pneumonia

    phase 3 small molecule active

    1 trial

  24. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources